Transdermal rotigotine for the perioperative management of Parkinson's disease.
Continuous delivery of antiparkinsonian medication during a perioperative period is desirable to avoid 'off'-symptom complications in surgical patients with concomitant Parkinson's disease (PD). Fourteen PD patients undergoing surgery under general anesthesia were switched from oral dopaminergic medication to transdermally delivered 24-h rotigotine (median dose 12 mg/24 h) for the perioperative period. Rotigotine treatment was considered feasible by patients, their anesthesiologists and neurologists with good control of PD symptoms and easy switching and re-switching of PD medication.
Wüllner
Ullrich
U
Department of Neurology, University Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany. wuellner@uni-bonn.de
Kassubek
Jan
J
Odin
Per
P
Schwarz
Michael
M
Naumann
Markus
M
Häck
Hermann-Josef
HJ
Boroojerdi
Babak
B
Reichmann
Heinz
H
D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D000768:Anesthesia, General; D000776:Anesthesiology; D001291:Attitude of Health Personnel; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009462:Neurology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery*; D019990:Perioperative Care; D010820:Physicians / Q000523:psychology; D011446:Prospective Studies; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage* / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine